Shares of Bioventus Inc. (NYSE:BVS – Get Rating) have received an average recommendation of “Hold” from the six research firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $8.80.
Several brokerages recently commented on BVS. Morgan Stanley reduced their target price on Bioventus from $11.00 to $5.00 and set an “overweight” rating on the stock in a report on Thursday, November 10th. JPMorgan Chase & Co. cut Bioventus from an “overweight” rating to an “underweight” rating in a report on Wednesday, November 9th. Craig Hallum cut Bioventus from a “buy” rating to a “hold” rating and set a $10.00 target price on the stock. in a report on Tuesday, November 22nd. Canaccord Genuity Group cut Bioventus from a “buy” rating to a “hold” rating and reduced their target price for the company from $18.00 to $6.00 in a report on Wednesday, November 9th. Finally, Canaccord Genuity Group cut Bioventus from a “buy” rating to a “hold” rating and cut their price target for the stock from $18.00 to $6.00 in a report on Wednesday, November 9th.
Hedge Funds Weigh In On Bioventus
A number of institutional investors and hedge funds have recently modified their holdings of BVS. First Horizon Advisors Inc. bought a new position in shares of Bioventus in the 2nd quarter worth $50,000. Victory Capital Management Inc. lifted its holdings in shares of Bioventus by 88.5% in the 2nd quarter. Victory Capital Management Inc. now owns 43,747 shares of the company’s stock worth $298,000 after purchasing an additional 20,539 shares in the last quarter. Strs Ohio lifted its holdings in shares of Bioventus by 6.0% in the 2nd quarter. Strs Ohio now owns 28,100 shares of the company’s stock worth $191,000 after purchasing an additional 1,600 shares in the last quarter. Amalgamated Bank bought a new position in shares of Bioventus in the 1st quarter worth $60,000. Finally, Swiss National Bank bought a new position in shares of Bioventus in the 2nd quarter worth $487,000. 46.88% of the stock is currently owned by institutional investors.
Bioventus Stock Performance
Bioventus (NYSE:BVS – Get Rating) last released its quarterly earnings data on Monday, November 21st. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.13 by ($0.08). Bioventus had a negative net margin of 24.61% and a positive return on equity of 7.87%. The firm had revenue of $128.66 million during the quarter, compared to analyst estimates of $141.77 million. On average, equities research analysts predict that Bioventus will post 0.24 earnings per share for the current year.
Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.